Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck
Metastatic Melanoma
Non-small Cell Lung Cancer

Interventions: Biological: LN-145
Biological: Lifileucel
Biological: LN-145-S1
Drug: Pembrolizumab
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-08-24

Last Posted Date: 2024-04-08

Lead Sponsor: Iovance Biotherapeutics, Inc.

Target Recruit Count: 178

Registration Number: NCT03645928

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇬🇧
The Royal Marsden NHS Foundation Trust, London, England, United Kingdom
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 42 locations

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Phase 2

Suspended

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Esophageal Adenocarcinoma
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Gastroesophageal Junction Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Biological: Ipilimumab
Biological: Nivolumab
Drug: Paclitaxel
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2018-07-30

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 278

Registration Number: NCT03604991

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Henry Ford Saint John Hospital - Macomb Medical, Macomb, Michigan, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 487 locations

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Phase 1

Recruiting

Conditions: Recurrent Meningioma
Grade 3 Meningioma
Grade 2 Meningioma

Interventions: Procedure: Biospecimen Collection
Procedure: Echocardiography
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Radiation: Stereotactic Radiosurgery

First Posted Date: 2018-07-30

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT03604978

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 27 locations

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2018-07-26

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03600155

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab +/- Ipilimumab in Patients with Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-07-19

Last Posted Date: 2024-10-18

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 185

Registration Number: NCT03591731

Locations: 🇫🇷
Paris - Curie, Paris, France
🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Avignon - CH, Avignon, France

and more 4 locations

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
SCLC

Interventions: Drug: Nivolumab
Drug: Plinabulin
Drug: Ipilimumab

First Posted Date: 2018-07-03

Last Posted Date: 2024-11-12

Lead Sponsor: Salma Sabbour

Target Recruit Count: 39

Registration Number: NCT03575793

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 5 locations

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Paclitaxel

First Posted Date: 2018-06-29

Last Posted Date: 2023-07-03

Lead Sponsor: Jeffrey Clarke

Target Recruit Count: 46

Registration Number: NCT03573947

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Phase 2

Completed

Conditions: Metastatic Cancer
Solid Tumor
Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-06-27

Last Posted Date: 2024-08-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 56

Registration Number: NCT03570619

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Entinostat
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-06-11

Last Posted Date: 2022-01-12

Lead Sponsor: Roberto Pili

Target Recruit Count: 18

Registration Number: NCT03552380

Locations: 🇺🇸
Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pembrolizumab
Procedure: Core Biopsy/Cryoablation
Procedure: Breast Surgery
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-24

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 80

Registration Number: NCT03546686

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Providence Cancer Institute, Portland, Oregon, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy